Catalyst
Slingshot members are tracking this event:
Kadmon Initiates Phase 2 Clinical Trial Evaluating Tesevatinib in Glioblastoma
Do you think this event is important to the companies below? How will it affect their stock price?
| Related Companies | Importance
|
Impact on Stocks
|
||||
|---|---|---|---|---|---|---|
| KDMN |
|
|
||||
Slingshot Insights Explained
Catalyst Date
Occurred on:
Aug 29, 2016
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
Tesevatinib, Glioblastoma, Oral Tyrosine Kinase Inhibitor, Blood-brain Barrier, Egfr-mutant Non-small Cell Lung Cancer
